HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share.
Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share.